Financial releases

Crossject appoints Dan Chiche, MD as Chief Medical Officer North America

Crossject announces highly successful closing of its €8 million rights offering

Crossject announces publication of clinical data on ZEPIZURE ® in Neurology and Therapy

Crossject signs a geographic extension of ZEPIZURE® commercialization agreement in Europe

Crossject announces a rights issue for approximately €8 million to support the registration of ZEPIZURE® and its continued expansion in the U.S.

Crossject reports audited financial results for 2023

Crossject advances in its U.S. Strategy and reports Financial Results for 2023

Crossject gender equality score reaches 96/100 in 2024

Crossject obtains a financing up to €12 million, in two tranches

Crossject provides strategic update on priorities for 2024